Evotec returns Roche compound for Alzheimer's disease after smoking cessation misfire
This article was originally published in Scrip
Executive Summary
Evotec stands to gain up to $830 million plus double-digit royalties under its latest deal signed with Roche, which is acquiring rights to a Phase I monoamine oxidase type B (MAO-B) inhibitor ready for development for Alzheimer's disease (AD). The compound, EVT 302, is potentially exciting because it may be able to alter the course of the disease and provide greater slowing of the progression of symptoms, whereas currently marketed therapies and many in development aim to treat the symptoms.